FDA approves GW drug trial

The biotech reported a rise in revenue in the 6 months ended March 31. It posted a loss in profit vs. a gain in the 6-month period a year ago. GW Pharmaceuticals (GWPH) got Investigational New Drug status from the FDA for a Phase 2/3 clinical trial of its childhood epilepsy drug, Epidiolex, for use in the treatment of Dravet Syndrome. GW expects to start the trial in the 2nd half of the year. Shares fell 6.3% to 69.81.

Advertisement